Steven Attia

7.0k citations

140 papers · 2.1k indexed · 1 hit paper · h-index 23

Impact in

Gastroenterology top 1%
- Gastrointestinal Tumor Research and Treatment
Pulmonary and Respiratory Medicine top 2%
- Sarcoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes

Papers in

Gastroenterology 28
- Gastrointestinal Tumor Research and Treatment 28
Pulmonary and Respiratory Medicine 98
- Sarcoma Diagnosis and Treatment 78
- Gastric Cancer Management and Outcomes 17

Co-authors: Robin L. Jones Scott H. Okuno Robert G. Maki Patrick Schöffski Richard F. Riedel Suzanne George Mark Agulnik Jean‐Yves Blay
Journals: Journal of Clinical Oncology (68 papers)Annals of Oncology (11 papers)Clinical Cancer Research (3 papers)Cancer Chemotherapy and Pharmacology (3 papers)Cancer (2 papers)
Partner nations: United States United Kingdom France

In The Last Decade

Steven Attia

128 papers receiving 2.1k citations

Hit Papers

align trajectories log scale

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial 2020 · 251 citations

Peers

Countries citing papers authored by Steven Attia

Since Specialization

Citations

This map shows the geographic impact of Steven Attia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Attia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Attia more than expected).

Fields of papers citing papers by Steven Attia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Attia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Attia. The network helps show where Steven Attia may publish in the future.

Co-authors

The 25 scholars most cited alongside Steven Attia, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Steven Attia Line = papers co-authored together Steven Attia links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial Journal of Clinical Oncology ·Ravin Ratan, Bernd Kasper, Thierry Alcindor, Patrick Schöffski, Winette T.A. van der Graaf, Noah Federman, Nam Q. Bui, Gina Z. D’Amato, Richard F. Riedel, Steven Attia, Sant P. Chawla, Esra Eraslan Aydemir, 春子杉田, Ana B. Oton, Теплоухова Мария Вячеславовна, Shengfan Zhou, Mrinal M. Gounder	2025	0
2	67MO Long-term nirogacestat treatment in adult patients with desmoid tumors: Updated efficacy and safety from the phase III DeFi trial ESMO Open ·Ivan Nicholas Chew, Maureen J. MacDonald, LU Ming-x, Winette T.A. van der Graaf, S. Swan, Nam Bui, Gina Z. D’Amato, Mohamad Sattar Rasul, Steven Attia, G. Fllippone, Yu‐De Chu, Robert Cohen, Ana B. Oton, R. M. Amkhadov, 春子杉田, Murugesan Gounder	2025	1
3	Molecular markers of proliferation, DNA repair, and immune infiltration defines high-risk subset of resectable retroperitoneal sarcomas Surgical Oncology ·Nathan D. Seligson, Yan W. Asmann, G. Espadas-Garcia, Cedric Barlet, Mark Edgar, Steven Attia, Keith L. Knutson, Sanjay P. Bagaria	2024	1
4	Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma Journal of Clinical Oncology ·Brian A. Van Tine, Matthew Ingham, Steven Attia, Christian F. Meyer, John D. Baird, Esther M. Brooks-Asplund, 添田雄二, Ronald Kong, Anthony Mwatha, Rolf Grutter, Marla Weetall, Robert J. Spiegel, Gary K. Schwartz	2024	3
5	Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology ·Andrew J. Wagner, Jonathan C. Trent, Steven Attia, Mark Agulnik, Breelyn A. Wilky, William D. Tap, Margaret von Mehren, Elizabeth J. Davis, Zhen‐Gong Ge, Nisha Shah, 차재웅, Julia Lawrence, Lei Sun, Neeta Somaiah	2024	1
6	Efficacy and safety of nirogacestat in patients with desmoid tumor and adenomatous polyposis coli (APC) mutation: Phase 3 DeFi analyses. Journal of Clinical Oncology ·Bernd Kasper, Noah Federman, Peter Reichardt, Steven Attia, Allison Lim, Sivaprakasam Manjambigai, Sunny Cho, Richard F. Riedel	2024	3
7	Deep Learning-Based Auto Contouring of Mandibular Sub-Volumes Based on the ClinRad System for Spatial Localization of Osteoradionecrosis of the Jaw International Journal of Radiation OncologyBiologyPhysics ·P. Israiloff, Kareem A. Wahid, F. M. M. MASSAGARDI, M. I. Tiplady, Hong Liu, Marijn Van Gils, H. Duminil-Copin, Y. I. Kim, Wenhao Le, Steven Attia, 解植春, Mohamed A. Naser, Stephen Y. Lai, Ricardo Mejía Gutiérrez, Amy C. Moreno	2024	0
8	Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE. Journal of Clinical Oncology ·John Zalcberg, Robin L. Jones, Jean‐Yves Blay, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, Yoon‐Koo Kang, Albiruni Ryan Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Ángel Antonio García Marrero, F. Ferroni, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Sebastian Bauer, Michael C. Heinrich, (unknown)	2024	2
9	Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology ·Michael C. Heinrich, Neeta Somaiah, Jonathan C. Trent, Breelyn A. Wilky, Melissa Burgess, Arun S. Singh, Steven Attia, Mark Agulnik, William D. Tap, Sebastian Bauer, Robin L. Jones, César Serrano, Zhen‐Gong Ge, 차재웅, Julia Lawrence, Andrew J. Wagner	2024	1
10	Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma Clinical and Translational Science ·Lan Gao, Diksha Kaushik, Brian A. Van Tine, Matthew Ingham, Steven Attia, Christian F. Meyer, Gary K. Schwartz, Pius Maliakal, John D. Baird, Jiyuan Ma, Rosemary Barrett, 添田雄二, Rolf Grutter, Ronald Kong	2023	1
11	Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas Cancers ·Steven Attia, Víctor M. Villalobos, Nadia Hindi, Andrew J. Wagner, Bartosz Chmielowski, Gerard J. Oakley, Patrick Peterson, L. Shaw, Robin L. Jones, Mark A. Dickson	2023	1
12	Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial Journal of Clinical Oncology ·Sebastian Bauer, Robin L. Jones, Jean‐Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Mariel Orduña Rodríguez, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Ying Su, Julie Meade, Tao Wang, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Michael C. Heinrich	2022	61
13	A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes Clinical Cancer Research ·Benjamin K. Wilke, Hillary W. Garner, Joseph M. Bestic, FCC Louzada, Michael G. Heckman, Jennifer J. Schoch, Steven Attia	2022	1
14	Health-Related Quality of Life and Pain with Selinexor in Patients with Advanced Dedifferentiated Liposarcoma Future Oncology ·Mrinal M. Gounder, Albiruni R. Abdul Razak, Adrienne M. Gilligan, Hoyee Leong, Xiwen Ma, Neeta Somaiah, Sant P. Chawla, Javier Martín‐Broto, Giovanni Grignani, Scott M. Schuetze, Bruno Vincenzi, Andrew J. Wagner, Bartosz Chmielowski, Robin L. Jones, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Richard F. Riedel, Steven Attia	2021	13
15	Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study Clinical Cancer Research ·Sebastian Bauer, Michael C. Heinrich, Suzanne George, John Zalcberg, César Serrano, Hans Gelderblom, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Julie Meade, Ying Su, Rodrigo Ruiz‐Soto, Jean‐Yves Blay, Margaret von Mehren, Patrick Schöffski	2021	33
16	An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma European Journal of Cancer ·Mark Agulnik, Brian Schulte, Steven I. Robinson, Angela C. Hirbe, Kevin R. Kozak, Sant P. Chawla, Steven Attia, Alfred Rademaker, M W J Beard, Wang Xinwei, Amit J. Jhala, Varun Monga, Mohammed Milhem, Scott H. Okuno, Brian A. Van Tine	2021	17
17	1622MO Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study Annals of Oncology ·John Zalcberg, Michael C. Heinrich, Suzanne George, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, César Serrano, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Wuxiong, Gabriella Santacecilia, Kelvin Shi, Rodrigo Ruiz‐Soto, Margaret von Mehren, Jean‐Yves Blay	2020	1
18	O-13 Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUS Annals of Oncology ·César Serrano, Michael C. Heinrich, Suzanne George, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Joseph, Gabriella Santacecilia, Kelvin Shi, Jean‐Yves Blay, Margaret von Mehren	2020	4
19	Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma Journal of Clinical Oncology ·Lara E. Davis, Vanessa Bolejack, Christopher W. Ryan, Kristen N. Ganjoo, Elizabeth T. Loggers, Sant P. Chawla, Mark Agulnik, Michael B. Livingston, Damon R. Reed, エルネットリックス事業部, Daniel A. Rushing, Scott H. Okuno, Denise K. Reinke, Richard F. Riedel, Steven Attia, Leo Mascarenhas, Robert G. Maki	2019	174
20	Recurrent myxoinflammatory fibroblastic sarcoma: a case report Clinical Case Reports ·吴善臻, Daniel Miller, B Rathnayake, Steven Attia, C. Shruthisree, Cherise Cortese, J Saretzki, Robert C. Miller	2017	2

About Steven Attia

Steven Attia is a scholar working on Gastroenterology, Pulmonary and Respiratory Medicine, Oncology, Pathology and Forensic Medicine and Cancer Research, having authored 140 papers that have together received 2.1k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (78 papers), Vascular Tumors and Angiosarcomas (29 papers), Gastrointestinal Tumor Research and Treatment (28 papers), Cardiac tumors and thrombi (22 papers), CAR-T cell therapy research (18 papers), Gastric Cancer Management and Outcomes (17 papers), Lymphoma Diagnosis and Treatment (12 papers) and Soft tissue tumor case studies (10 papers). The work is most often cited by research in Gastroenterology (418 citations), Pulmonary and Respiratory Medicine (1.4k citations), Oncology (1.0k citations), Pathology and Forensic Medicine (327 citations) and Cardiology and Cardiovascular Medicine (377 citations). Steven Attia has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Robin L. Jones, Scott H. Okuno, Robert G. Maki, Patrick Schöffski, Richard F. Riedel, Suzanne George, Mark Agulnik, Jean‐Yves Blay, Margaret von Mehren and Hans Gelderblom. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, Cancer Chemotherapy and Pharmacology and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact